ClinicalTrials.gg
CompletedNCT01428583Updated Nov 21, 2016Results posted

Safety Study of Oxycodone Hydrochloride and Naltrexone Hydrochloride Extended-Release Capsules in Subjects With Moderate to Severe Chronic Noncancer Pain

A Phase 3 interventional study of oxycodone HCl and naltrexone HCl extended-release capsules in Chronic Noncancer Pain, sponsored by Pfizer. Completed at 32 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-11-21.

Sponsored by Pfizer · Phase 3, Interventional, and Supportive care

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
395
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 50 studies testing oxycodone in Pain — 4 open to participants now, 5 under way, 1 of them phase 3. Oxycodone · Pain.

Enrollment
4th of 50
395 · median 67
Started
2010
with 2 others
Phase 3
10 of 50
1 open now
Registered
12th of 50
by date
Lead sponsor
2 of 50
Pfizer

Among the 50 studies testing oxycodone in Pain, this one is the 4th largest by enrollment, is one of 3 that started in 2010, is one of 10 in phase 3, and was the 12th registered.

Pain

10,069 studies on the registry are indexed under Pain; 1,651 are open to participants now.

Browse Pain studies →

Open to participants now

4 of the 50 studies testing oxycodone in Pain are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About oxycodone

Oxycodone: first FDA approval 1950 (PERCODAN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 928 Pain studies recruiting now, 383 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 222 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies testing oxycodone in Pain, or all of them as a file.
02

Study summary

The study will provide information to assess the benefits versus risks of extended exposure to oxycodone HCl and naltrexone HCl extended-release capsules in a chronic noncancer pain population.

03

Conditions studied

  • Chronic Noncancer Pain

Browse trials for

Keywords

  • Chronic noncancer pain
  • oxycodone
  • naltrexone
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject has moderate to severe chronic noncancer pain (duration of at least 3 months) requiring a continuous around-the-clock opioid analgesic for an extended period of time. Conditions may include, but are not limited to, osteoarthritis, chronic low back pain, or other opioid -responsive pain conditions.
  • Subject agrees to refrain from taking opioid medications other than study drug during the study. (The exception is during the Pre-Treatment Period when the subject may continue current opioid therapy to guide first 4 weeks of the Treatment Period when the subject may administer immediate-release oxycodone to support conversion to study drug.)

Exclusion criteria

Exclusion Criteria:

  • Subject has moderate or severe chronic pain due to cancer, migraine, recent trauma, infection, or other pain expected to be short-term (duration less than 3 months).
  • Subject has a documented history of alcohol or drug abuse within 1 year prior to study entry that in the Investigator's judgment would impact subject participation.
  • Subject has ongoing or active alcohol or drug abuse that in the Investigator's judgment would impact subject participation.
  • Subject has a positive urine drug test for illicit drug use or medications at screening without legitimate medical explanation.
  • Subject has a medical condition (e.g., cardiovascular, neurological, renal, hepatic, pulmonary, gastrointestinal, endocrine, hematological, immunological, rheumatological, metabolic, or psychiatric) or physical examination, vital signs (VS), 12-lead (ECG), clinical laboratory abnormalities that in the opinion of the Investigator would impact the safety of the subject during study participation.
  • If female, the subject is pregnant or breast-feeding.
  • Subject has a known history or known to oxycodone, oxycodone salts, naltrexone or acetaminophen,or pharmacological similar compounds.
  • Subject is historically non-responsive to oxycodone treatment or requires greater than 160 mg oxycodone in a 24-hour time interval.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Supportive care
Masking
None (open label)
Enrollment
395 participants (actual)

Study arms

  • Experimental
    oxycodone HCl and naltrexone HCl extended-release capsules

    Drug: oxycodone HCl and naltrexone HCl extended-release capsules

Interventions

  • Drugoxycodone HCl and naltrexone HCl extended-release capsules

    Drug pages: Oxycodone · Naltrexone

    Daily dose range of 20 mg to 160 mg of the oxycodone component in a 24 hour time interval, administered twice daily approximately 12 hours apart (At the discretion of the Investigator, oxycodone HCl and naltrexone HCl extended-release capsules may be administered once daily, at 24 hour intervals.)

    Also known as: ALO-02

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (AEs) and Adverse Reactions

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An AE that was attributed to study drug in a participant who received study drug was defined as an adverse reaction. Treatment-emergent are events between first dose of study drug and up to end of study (2 weeks post-end of month 12) that were absent before treatment or that worsened relative to pretreatment state.

    Time frame: Baseline up to end of study (2 weeks post-end of month 12)

Secondary outcomes

  1. Number of Participants With Treatment Emergent (TE) Adverse Events (AEs) Based on Intensity

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Intensity of adverse event was defined on the basis of severity of an event and was classified as; mild (does not interfere with participant's usual function), moderate (interferes to some extent with participant's usual function) and severe (interferes significantly with participant's usual function). Treatment-emergent are events between first dose of study drug and up to end of study (2 weeks post-end of month 12) that were absent before treatment or that worsened relative to pretreatment state.

    Time frame: Baseline up to end of study (2 weeks post-end of month 12)

  2. Percentage of Participants With Clinical Opiate Withdrawal Scale (COWS) Score

    The presence and level of clinical opiate withdrawal signs or symptoms was determined by clinician-administered, clinical opiate withdrawal scale (COWS). It contains 11 common opiate withdrawal signs or symptoms rated by clinician (resting pulse rate, gastrointestinal upset, sweating, tremor, restlessness, yawning, pupil size, anxiety or irritability, bone or joint aches, gooseflesh skin, runny nose or tearing), rated on either 3-point, 4-point or 5-point scale, higher score indicated more symptoms of withdrawal. The total score is the sum of all items, ranging from 0 to 48, higher score indicated severe withdrawal. Participants were categorized as less than mild (score 0-4) mild (score 5-12), moderate (score 13-24), moderately severe (score 25-36) or severe (score greater than 36). Percentage of participants with mild (score 5-12), moderate (score 13-24), moderately severe (score 25-36) or severe (score greater than 36) were reported.

    Time frame: Baseline up to Month 12

  3. Subjective Opiate Withdrawal Scale (SOWS) Score

    The presence and level of clinical opiate withdrawal signs or symptoms was determined by participant-reported instrument, subjective opiate withdrawal scale (SOWS). It contains 16 symptoms of opiate withdrawal rated by the participant (anxiety, yawning, sweating, tearing, running nose, goose bumps, shaking, hot flashes, cold flashes, bone or muscle aches, restlessness, nauseous, vomiting, muscle twitch, stomach cramps and feel like using now). Each item is rated on a 5-point scale (0= not at all, 1= a little, 2= moderate, 3= quite a bit, 4= extreme). The total score is the sum of all items, ranging from 0 to 64, higher score indicated severe withdrawal.

    Time frame: Baseline, Week 1, 4, Month 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12

Other outcomes

  1. Observed Steady-state Plasma Concentrations (Cobs) of Oxycodone

    Time frame: Week 1, 4, Month 2, 3, 6, 9, 12 or early termination

  2. Observed Steady-state Plasma Concentrations (Cobs) of Noroxycodone

    Noroxycodone was a metabolite of Oxycodone.

    Time frame: Week 1, 4, Month 2, 3, 6, 9, 12 or early termination

  3. Observed Steady-state Plasma Concentrations (Cobs) of Naltrexone

    Time frame: Week 1, 4, Month 2, 3, 6, 9, 12 or early termination

  4. Observed Steady-state Plasma Concentrations (Cobs) of 6-Beta-naltrexol

    6-Beta-naltrexol was a metabolite of naltrexone.

    Time frame: Week 1, 4, Month 2, 3, 6, 9, 12 or early termination

  5. Time to Stabilization of Study Medication

    Stabilization was considered to have occurred when: total daily dose of oxycodone and naltrexone remained unchanged for greater than or equal to (\>=) 3 consecutive days, daily acetaminophen used remained at 1 gram or less and immediate-release oxycodone was not being used as a rescue medication. Days to stabilization = date of stabilization - date of first dose + 1.

    Time frame: Baseline up to Month 12

  6. Duration of Exposure to Study Medication

    Duration of exposure to study medication during the course of the study was assessed.

    Time frame: Baseline up to 2 weeks after last dose

  7. Mean Daily Dose of Study Medication (Oxycodone Component)

    Time frame: Baseline- less than (<) Week 1, Week 1-<4, Week 4-<Month 2, Month 2-<3, Month 3-<4, Month 4-< 5, Month 5-<6, Month 6-<7, Month 7-<8, Month8-<9, Month 9-<10, Month 10-<11, Month 11-<12, Month 12-<End of study (2 weeks post end of Month 12)

  8. Number of Participants With Rescue Medication (Acetaminophen Tablets)

    Participants had acetaminophen up to 2 grams per day during the treatment period of the study as rescue medication.

    Time frame: Baseline- less than (<) Week 1, Week 1-<4, Week 4-<Month 2, Month 2-<3, Month 3-<4, Month 4-< 5, Month 5-<6, Month 6-<7, Month 7-<8, Month8-<9, Month 9-<10, Month 10-<11, Month 11-<12, Month 12-<End of study (2 weeks post end of Month 12)

  9. Percentage of Participants With Response to Urine Drug Test

    Participants with a positive urine drug test for illicit drug substances (marijuana, cocaine, amphetamines, methamphetamines, phencyclidine, and ecstasy), or unexpected drug substances (those other than reported by the participant as therapeutic concomitant medications such as opiates and methadone), or a negative urine test for the expected opioid (oxycodone) was assessed.

    Time frame: Screening, Week 4, Month 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or early termination

  10. Percentage of Participants With Current Opioid Misuse Measure (COMM) Score of 9 or Above

    The COMM is a 17-item self-report questionnaire to monitor for aberrant medication-related behaviors among chronic pain participants. Participants are asked to indicate the frequency of individual behaviors on a scale from 0 to 4 (0 = never, 1 = seldom, 2 = sometimes, 3 = often, 4= very often). The total COMM score is the sum of the 17 item scores with a range from 0 to 68. Higher score indicated a higher risk for aberrant medication- related behavior. A score of 9 or higher was defined as high risk for aberrant medication- related behavior.

    Time frame: Baseline, Week 4, Month 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or early termination

  11. Mean Daily Dose of Immediate-release Oxycodone as Rescue Medication

    Immediate-release oxycodone as a single ingredient product was used as a rescue medication only during the first 4 weeks of the treatment period to support the initiation of oxycodone HCl and naltrexone HCl treatment.

    Time frame: Up to Week 4

  12. Participants Global Assessment of Treatment Satisfaction

    Participant global assessment of treatment satisfaction was scored on a 5-point categorical scale based on response to the question "Please rate your overall satisfaction with the study drug you received?" where 1 = very dissatisfied, 2 = dissatisfied, 3 = neither satisfied nor dissatisfied, 4 = satisfied, 5 = very satisfied.

    Time frame: Week 1, 4, Month 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, end of treatment

  13. Mean Change From Baseline in Pain Right Now Score at Weeks 1, 4, Months 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 12 or Early Termination

    The pain intensity scale consisted of 4 questions (pain at its worst in the last 24 hours, pain at its least in the last 24 hours, pain on the average in the last 24 hours and pain right now) each scored on an 11-point numerical rating scale, where 0 = no pain and 10 = pain as bad as you can imagine. "Pain right now" was reported.

    Time frame: Baseline, Week 1, 4, Months 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 12 or Early Termination (ET)

  14. Mean Change From Baseline in Average Pain Score at Weeks 1, 4, Months 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 12 or Early Termination

    The pain intensity scale consisted of 4 questions (pain at its worst in the last 24 hours, pain at its least in the last 24 hours, pain on the average in the last 24 hours and pain right now) each scored on an 11-point numerical rating scale, where 0 = no pain and 10 = pain as bad as you can imagine. Pain on average in the last 24 hours" was reported.

    Time frame: Baseline, Week 1, 4, Months 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 12 or Early Termination

  15. Mean Change From Baseline in Worst Pain Score at Weeks 1, 4, Months 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 12 or Early Termination

    The pain intensity scale consisted of 4 questions (pain at its worst in the last 24 hours, pain at its least in the last 24 hours, pain on the average in the last 24 hours and pain right now) each scored on an 11-point numerical rating scale, where 0 = no pain and 10 = pain as bad as you can imagine. "Pain at its worst in the last 24 hours" was reported.

    Time frame: Baseline, Week 1, 4, Months 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 12 or Early Termination

07

Results

Posted Nov 21, 2016
Limitations and caveats
Outcome measure reporting of Participants With Response to Urine Drug Test were based on qualitative point of contact results only.

Participant flow

Participant flow — Overall Study
MilestoneOxycodone Hydrochloride (HCl) and Naltrexone HCl
Started395
Completed158
Not completed237
Withdrew: Adverse event75
Withdrew: Withdrawal by subject51
Withdrew: Lack of efficacy37
Withdrew: Lost to follow-up17
Withdrew: Death1
Withdrew: Pregnancy1
Withdrew: Protocol violation1
Withdrew: Physician decision12
Withdrew: Non-compliant25
Withdrew: Confirmed positive urine drug test8
Withdrew: Sponsor's request3
Withdrew: Other6

Outcome measures

PrimaryNumber of Participants With Treatment-Emergent Adverse Events (AEs) and Adverse Reactions

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An AE that was attributed to study drug in a participant who received study drug was defined as an adverse reaction. Treatment-emergent are events between first dose of study drug and up to end of study (2 weeks post-end of month 12) that were absent before treatment or that worsened relative to pretreatment state.

Time frame:
Baseline up to end of study (2 weeks post-end of month 12)
Reported as:
Number · participants
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Adverse Reactions
participantsOxycodone Hydrochloride (HCl) and Naltrexone HCl
Adverse event (all causalities)343
Adverse reaction207
SecondaryNumber of Participants With Treatment Emergent (TE) Adverse Events (AEs) Based on Intensity

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Intensity of adverse event was defined on the basis of severity of an event and was classified as; mild (does not interfere with participant's usual function), moderate (interferes to some extent with participant's usual function) and severe (interferes significantly with participant's usual function). Treatment-emergent are events between first dose of study drug and up to end of study (2 weeks post-end of month 12) that were absent before treatment or that worsened relative to pretreatment state.

Time frame:
Baseline up to end of study (2 weeks post-end of month 12)
Reported as:
Number · participants
Number of Participants With Treatment Emergent (TE) Adverse Events (AEs) Based on Intensity
participantsOxycodone Hydrochloride (HCl) and Naltrexone HCl
Mild94
Moderate202
Severe47
SecondaryPercentage of Participants With Clinical Opiate Withdrawal Scale (COWS) Score

The presence and level of clinical opiate withdrawal signs or symptoms was determined by clinician-administered, clinical opiate withdrawal scale (COWS). It contains 11 common opiate withdrawal signs or symptoms rated by clinician (resting pulse rate, gastrointestinal upset, sweating, tremor, restlessness, yawning, pupil size, anxiety or irritability, bone or joint aches, gooseflesh skin, runny nose or tearing), rated on either 3-point, 4-point or 5-point scale, higher score indicated more symptoms of withdrawal. The total score is the sum of all items, ranging from 0 to 48, higher score indicated severe withdrawal. Participants were categorized as less than mild (score 0-4) mild (score 5-12), moderate (score 13-24), moderately severe (score 25-36) or severe (score greater than 36). Percentage of participants with mild (score 5-12), moderate (score 13-24), moderately severe (score 25-36) or severe (score greater than 36) were reported.

Time frame:
Baseline up to Month 12
Reported as:
Number · percentage of participants
Percentage of Participants With Clinical Opiate Withdrawal Scale (COWS) Score
percentage of participantsOxycodone Hydrochloride (HCl) and Naltrexone HCl
Mild (score 5-12)13.2
Moderate (score 13-24)0.0
Moderately severe (score 25-36)0.3
Severe (score greater than 36)0.0
SecondarySubjective Opiate Withdrawal Scale (SOWS) Score

The presence and level of clinical opiate withdrawal signs or symptoms was determined by participant-reported instrument, subjective opiate withdrawal scale (SOWS). It contains 16 symptoms of opiate withdrawal rated by the participant (anxiety, yawning, sweating, tearing, running nose, goose bumps, shaking, hot flashes, cold flashes, bone or muscle aches, restlessness, nauseous, vomiting, muscle twitch, stomach cramps and feel like using now). Each item is rated on a 5-point scale (0= not at all, 1= a little, 2= moderate, 3= quite a bit, 4= extreme). The total score is the sum of all items, ranging from 0 to 64, higher score indicated severe withdrawal.

Time frame:
Baseline, Week 1, 4, Month 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
Reported as:
Mean · units on a scale
Subjective Opiate Withdrawal Scale (SOWS) Score
units on a scaleOxycodone Hydrochloride (HCl) and Naltrexone HCl
Baseline (n= 395)5.4 ± 5.49
Week 1 (n= 362)4.6 ± 6.15
Week 4 (n= 307)3.6 ± 4.32
Month 2 (n= 252)3.6 ± 4.70
Month 3 (n= 221)3.3 ± 4.53
Month 4 (n= 210)2.9 ± 4.30
Month 5 (n= 198)3.2 ± 4.56
Month 6 (n= 190)2.5 ± 3.27
Month 7 (n= 185)2.4 ± 4.07
Month 8 (n= 180)2.5 ± 3.74
Month 9 (n= 174)2.4 ± 4.08
Month 10 (n= 167)2.2 ± 3.25
Month 11 (n= 162)2.3 ± 3.53
Month 12 (n= 154)2.4 ± 4.09
Other pre-specifiedObserved Steady-state Plasma Concentrations (Cobs) of Oxycodone
Time frame:
Week 1, 4, Month 2, 3, 6, 9, 12 or early termination

No measurements were reported for this outcome.

Other pre-specifiedObserved Steady-state Plasma Concentrations (Cobs) of Noroxycodone

Noroxycodone was a metabolite of Oxycodone.

Time frame:
Week 1, 4, Month 2, 3, 6, 9, 12 or early termination

No measurements were reported for this outcome.

Other pre-specifiedObserved Steady-state Plasma Concentrations (Cobs) of Naltrexone
Time frame:
Week 1, 4, Month 2, 3, 6, 9, 12 or early termination

No measurements were reported for this outcome.

Other pre-specifiedObserved Steady-state Plasma Concentrations (Cobs) of 6-Beta-naltrexol

6-Beta-naltrexol was a metabolite of naltrexone.

Time frame:
Week 1, 4, Month 2, 3, 6, 9, 12 or early termination

No measurements were reported for this outcome.

Other pre-specifiedTime to Stabilization of Study Medication

Stabilization was considered to have occurred when: total daily dose of oxycodone and naltrexone remained unchanged for greater than or equal to (\>=) 3 consecutive days, daily acetaminophen used remained at 1 gram or less and immediate-release oxycodone was not being used as a rescue medication. Days to stabilization = date of stabilization - date of first dose + 1.

Time frame:
Baseline up to Month 12
Reported as:
Median · days
Time to Stabilization of Study Medication
daysOxycodone Hydrochloride (HCl) and Naltrexone HCl
Time to Stabilization of Study Medication11.0 (3 to 133)
Other pre-specifiedDuration of Exposure to Study Medication

Duration of exposure to study medication during the course of the study was assessed.

Time frame:
Baseline up to 2 weeks after last dose
Reported as:
Median · days
Duration of Exposure to Study Medication
daysOxycodone Hydrochloride (HCl) and Naltrexone HCl
Duration of Exposure to Study Medication171.0 (1 to 406)
Other pre-specifiedMean Daily Dose of Study Medication (Oxycodone Component)
Time frame:
Baseline- less than (<) Week 1, Week 1-<4, Week 4-<Month 2, Month 2-<3, Month 3-<4, Month 4-< 5, Month 5-<6, Month 6-<7, Month 7-<8, Month8-<9, Month 9-<10, Month 10-<11, Month 11-<12, Month 12-<End of study (2 weeks post end of Month 12)
Reported as:
Mean · milligram/day
Mean Daily Dose of Study Medication (Oxycodone Component)
milligram/dayOxycodone Hydrochloride (HCl) and Naltrexone HCl
Baseline-less than (<) Week 1 (n= 378)38.6 ± 81.27
Week 1-<4 (n= 344)51.7 ± 35.53
Week 4-<Month 2 (n= 292)62.8 ± 42.65
Month 2-< 3 (n= 238)66.1 ± 40.35
Month 3-<4 (n= 217)68.0 ± 40.36
Month 4-< 5 (n= 205)68.6 ± 41.49
Month 5-<6 (n= 193)71.5 ± 43.58
Month 6-<7 (n= 183)73.1 ± 43.22
Month 7- <8 (n= 183)76.7 ± 43.76
Month 8-<9 (n= 177)77.7 ± 45.67
Month 9-<10 (n= 169)76.5 ± 44.58
Month 10- <11 (n= 163)77.9 ± 44.45
Month 11- <12 (n= 160)76.2 ± 43.14
Month 12- <End of study (n= 82)26.9 ± 22.79
Other pre-specifiedNumber of Participants With Rescue Medication (Acetaminophen Tablets)

Participants had acetaminophen up to 2 grams per day during the treatment period of the study as rescue medication.

Time frame:
Baseline- less than (<) Week 1, Week 1-<4, Week 4-<Month 2, Month 2-<3, Month 3-<4, Month 4-< 5, Month 5-<6, Month 6-<7, Month 7-<8, Month8-<9, Month 9-<10, Month 10-<11, Month 11-<12, Month 12-<End of study (2 weeks post end of Month 12)
Reported as:
Number · participants
Number of Participants With Rescue Medication (Acetaminophen Tablets)
participantsOxycodone Hydrochloride (HCl) and Naltrexone HCl
Baseline-<Week 1 (n= 387)256
Week 1-<4 (n= 361)204
Week 4-<Month 2 (n= 305)167
Month 2-<3 (n= 252)124
Month 3-<4 (n= 222)120
Month 4-<5 (n= 209)112
Month 5-<6 (n= 199)104
Month 6-<7 (n= 191)96
Month 7-<8 (n= 185)96
Month8-<9 (n= 179)93
Month 9-<10 (n= 172)79
Month 10-<11 (n= 167)80
Month 11-<12 (n= 163)85
Month 12-<End of study (n= 95)30
Other pre-specifiedPercentage of Participants With Response to Urine Drug Test

Participants with a positive urine drug test for illicit drug substances (marijuana, cocaine, amphetamines, methamphetamines, phencyclidine, and ecstasy), or unexpected drug substances (those other than reported by the participant as therapeutic concomitant medications such as opiates and methadone), or a negative urine test for the expected opioid (oxycodone) was assessed.

Time frame:
Screening, Week 4, Month 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or early termination
Reported as:
Number · percentage of participants
Percentage of Participants With Response to Urine Drug Test
percentage of participantsOxycodone Hydrochloride (HCl) and Naltrexone HCl
Screening (n= 393)86.8
Week 4 (n= 302)41.7
Month 2 (n= 251)43.0
Month 3 (n= 222)43.2
Month 4 (n= 211)39.3
Month 5 (n= 198)41.4
Month 6 (n= 190)44.2
Month 7 (n= 184)41.8
Month 8 (n= 179)44.1
Month 9 (n= 174)44.8
Month 10 (n= 167)44.3
Month 11 (n= 161)50.3
Month 12 or early termination (n= 343)57.1
Other pre-specifiedPercentage of Participants With Current Opioid Misuse Measure (COMM) Score of 9 or Above

The COMM is a 17-item self-report questionnaire to monitor for aberrant medication-related behaviors among chronic pain participants. Participants are asked to indicate the frequency of individual behaviors on a scale from 0 to 4 (0 = never, 1 = seldom, 2 = sometimes, 3 = often, 4= very often). The total COMM score is the sum of the 17 item scores with a range from 0 to 68. Higher score indicated a higher risk for aberrant medication- related behavior. A score of 9 or higher was defined as high risk for aberrant medication- related behavior.

Time frame:
Baseline, Week 4, Month 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or early termination
Reported as:
Number · percentage of participants
Percentage of Participants With Current Opioid Misuse Measure (COMM) Score of 9 or Above
percentage of participantsOxycodone Hydrochloride (HCl) and Naltrexone HCl
Baseline (n= 395)21.3
Week 4 (n= 302)8.9
Month 2 (n= 250)10.0
Month 3 (n= 217)8.3
Month 4 (n= 208)6.7
Month 5 (n= 197)5.1
Month 6 (n= 189)2.6
Month 7 (n= 185)3.2
Month 8 (n= 181)5.0
Month 9 (n= 174)5.7
Month 10 (n= 167)4.8
Month 11 (n= 162)3.7
Month 12 or early termination (n= 333)15.3
Other pre-specifiedMean Daily Dose of Immediate-release Oxycodone as Rescue Medication

Immediate-release oxycodone as a single ingredient product was used as a rescue medication only during the first 4 weeks of the treatment period to support the initiation of oxycodone HCl and naltrexone HCl treatment.

Time frame:
Up to Week 4

No measurements were reported for this outcome.

Other pre-specifiedParticipants Global Assessment of Treatment Satisfaction

Participant global assessment of treatment satisfaction was scored on a 5-point categorical scale based on response to the question "Please rate your overall satisfaction with the study drug you received?" where 1 = very dissatisfied, 2 = dissatisfied, 3 = neither satisfied nor dissatisfied, 4 = satisfied, 5 = very satisfied.

Time frame:
Week 1, 4, Month 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, end of treatment
Reported as:
Mean · unit on a scale
Participants Global Assessment of Treatment Satisfaction
unit on a scaleOxycodone Hydrochloride (HCl) and Naltrexone HCl
Week 1 (n= 361)3.3 ± 1.03
Week 4 (n= 304)3.8 ± 0.99
Month 2 (n= 251)3.9 ± 0.94
Month 3 (n= 220)4.1 ± 0.88
Month 4 (n= 209)4.1 ± 0.93
Month 5 (n= 197)4.2 ± 0.90
Month 6 (n= 190)4.2 ± 0.89
Month 7 (n= 185)4.2 ± 0.81
Month 8 (n= 181)4.2 ± 0.81
Month 9 (n= 174)4.2 ± 0.96
Month 10 (n= 167)4.3 ± 0.73
Month 11 (n= 162)4.3 ± 0.79
Month 12 (n= 154)4.2 ± 1.04
End of treatment (n= 372)3.6 ± 1.27
Other pre-specifiedMean Change From Baseline in Pain Right Now Score at Weeks 1, 4, Months 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 12 or Early Termination

The pain intensity scale consisted of 4 questions (pain at its worst in the last 24 hours, pain at its least in the last 24 hours, pain on the average in the last 24 hours and pain right now) each scored on an 11-point numerical rating scale, where 0 = no pain and 10 = pain as bad as you can imagine. "Pain right now" was reported.

Time frame:
Baseline, Week 1, 4, Months 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 12 or Early Termination (ET)
Reported as:
Mean · units on a scale
Mean Change From Baseline in Pain Right Now Score at Weeks 1, 4, Months 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 12 or Early Termination
units on a scaleOxycodone Hydrochloride (HCl) and Naltrexone HCl
Baseline (n= 386)5.6 ± 2.17
Change at Week 1 (n= 360)-0.6 ± 2.16
Change at Week 4 (n= 306)-1.3 ± 2.29
Change at Month 2 (n= 251)-1.6 ± 2.36
Change at Month 3 (n= 218)-1.7 ± 2.34
Change at Month 4 (n= 208)-1.8 ± 2.29
Change at Month 5 (n= 197)-1.8 ± 2.29
Change at Month 6 (n= 189)-1.8 ± 2.38
Change at Month 7 (n= 184)-1.7 ± 2.40
Change at Month 8 (n= 180)-1.8 ± 2.48
Change at Month 9 (n= 172)-1.8 ± 2.39
Change at Month 10 (n= 166)-1.7 ± 2.41
Change at Month 11 (n= 161)-1.9 ± 2.31
Change at Month 12 (n= 153)-1.9 ± 2.44
Change at Month 12/ET (n= 373)-1.4 ± 2.58
Other pre-specifiedMean Change From Baseline in Average Pain Score at Weeks 1, 4, Months 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 12 or Early Termination

The pain intensity scale consisted of 4 questions (pain at its worst in the last 24 hours, pain at its least in the last 24 hours, pain on the average in the last 24 hours and pain right now) each scored on an 11-point numerical rating scale, where 0 = no pain and 10 = pain as bad as you can imagine. Pain on average in the last 24 hours" was reported.

Time frame:
Baseline, Week 1, 4, Months 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 12 or Early Termination
Reported as:
Mean · unit on a scale
Mean Change From Baseline in Average Pain Score at Weeks 1, 4, Months 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 12 or Early Termination
unit on a scaleOxycodone Hydrochloride (HCl) and Naltrexone HCl
Baseline (n= 384)5.9 ± 1.74
Change at Week 1 (n= 357)-0.6 ± 1.64
Change at Week 4 (n= 303)-1.2 ± 1.95
Change at Month 2 (n= 250)-1.5 ± 2.11
Change at Month 3 (n= 219)-1.7 ± 2.12
Change at Month 4 (n= 206)-1.7 ± 2.04
Change at Month 5 (n= 196)-1.7 ± 2.02
Change at Month 6 (n= 189)-1.7 ± 2.11
Change at Month 7 (n= 184)-1.7 ± 2.17
Change at Month 8 (n= 180)-1.9 ± 2.12
Change at Month 9 (n= 173)-1.8 ± 2.21
Change at Month 10 (n= 166)-1.7 ± 2.26
Change at Month 11 (n= 161)-1.8 ± 2.02
Change at Month 12 (n= 153)-1.9 ± 2.23
Change at Month 12/ET (n= 372)-1.3 ± 2.32
Other pre-specifiedMean Change From Baseline in Worst Pain Score at Weeks 1, 4, Months 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 12 or Early Termination

The pain intensity scale consisted of 4 questions (pain at its worst in the last 24 hours, pain at its least in the last 24 hours, pain on the average in the last 24 hours and pain right now) each scored on an 11-point numerical rating scale, where 0 = no pain and 10 = pain as bad as you can imagine. "Pain at its worst in the last 24 hours" was reported.

Time frame:
Baseline, Week 1, 4, Months 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 12 or Early Termination
Reported as:
Mean · unit on a scale
Mean Change From Baseline in Worst Pain Score at Weeks 1, 4, Months 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 12 or Early Termination
unit on a scaleOxycodone Hydrochloride (HCl) and Naltrexone HCl
Baseline (n= 382)7.4 ± 1.63
Change at Week 1 (n= 354)-0.7 ± 1.96
Change at Week 4 (n= 301)-1.3 ± 2.24
Change at Month 2 (n= 248)-1.6 ± 2.39
Change at Month 3 (n= 219)-1.8 ± 2.32
Change at Month 4 (n= 208)-1.9 ± 2.12
Change at Month 5 (n= 197)-1.9 ± 2.41
Change at Month 6 (n= 189)-2.0 ± 2.30
Change at Month 7 (n= 184)-2.0 ± 2.43
Change at Month 8 (n= 180)-2.0 ± 2.31
Change at Month 9 (n= 173)-2.2 ± 2.48
Change at Month 10 (n= 166)-2.1 ± 2.50
Change at Month 11 (n= 161)-2.2 ± 2.41
Change at Month 12 (n= 153)-2.2 ± 2.44
Change at Month 12/ET (n= 368)-1.6 ± 2.52

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Oxycodone Hydrochloride (HCl) and Naltrexone HCl—26/395 (6.6%)272/395 (68.9%)
Most frequent serious events
Showing 10 of 28
Most frequent serious events
EventOxycodone Hydrochloride (HCl) and Naltrexone HCl
Acute myocardial infarctionCardiac disorders2/395
Non-cardiac chest painGeneral disorders2/395
PneumoniaInfections and infestations2/395
ConvulsionNervous system disorders2/395
NephrolithiasisRenal and urinary disorders2/395
Hypochromic anaemiaBlood and lymphatic system disorders1/395
Cardiac failure congestiveCardiac disorders1/395
Abdominal painGastrointestinal disorders1/395
Hiatus herniaGastrointestinal disorders1/395
Pancreatitis acuteGastrointestinal disorders1/395
Most frequent other events
Showing 10 of 15
Most frequent other events
EventOxycodone Hydrochloride (HCl) and Naltrexone HCl
NauseaGastrointestinal disorders100/395
ConstipationGastrointestinal disorders84/395
VomitingGastrointestinal disorders55/395
HeadacheNervous system disorders46/395
SomnolenceNervous system disorders37/395
DiarrhoeaGastrointestinal disorders36/395
FatigueGeneral disorders36/395
DizzinessNervous system disorders34/395
AnxietyPsychiatric disorders30/395
Back painMusculoskeletal and connective tissue disorders25/395

Baseline characteristics

Safety analysis set included all enrolled participants who had at least 1 dose of oxycodone HCl and naltrexone HCl extended-release capsules.

Age, Continuous
Age, Continuous(years)Oxycodone Hydrochloride (HCl) and Naltrexone HCl
Mean53.8 ± 12.10
Sex: Female, Male
Sex: Female, Male(Participants)Oxycodone Hydrochloride (HCl) and Naltrexone HCl
Female203
Male192
08

Study locations

32 sites
  • Avail Clinical Research, LLC
    Deland, Florida 32720, United States
  • Florida Institute of Medical Research
    Jacksonville, Florida 32257, United States
  • Drug Study Institute
    Jupiter, Florida 33458, United States
  • Ormond Medical Arts Pharmaceutical Research Center
    Ormond Beach, Florida 32174, United States
  • Peninsula Research, Inc.
    Ormond Beach, Florida 32174, United States
  • Accord Clinical Research
    Port Orange, Florida 32129, United States
  • Sarasota Pain Medicine Research
    Sarasota, Florida 34238, United States
  • Clinical Research of West Florida
    Tampa, Florida 33603, United States
  • Center for Prospective Outcome Studies, Inc.
    Atlanta, Georgia 30327, United States
  • Drug Studies America
    Marietta, Georgia 30060, United States
  • Georgia Institute for Clinical Research, LLC
    Marietta, Georgia 30060, United States
  • The Pain Treatment Center of the Bluegrass
    Lexington, Kentucky 40503, United States
  • Commonwealth Biomedical Research
    Madisonville, Kentucky 42431, United States
  • Crossroads Research
    Owings Mills, Maryland 21117, United States
  • DM Clinical Research
    Springfield, Massachusetts 01103, United States
  • MAPS Applied Research Center
    Edina, Minnesota 55435, United States
  • Mid-South Anesthesia Consultants
    Southaven, Mississippi 38671, United States
  • Healthcare Research, LLC
    Hazelwood, Missouri 64042, United States
  • Montana Neuroscience Institute
    Missoula, Montana 59802, United States
  • Comprehensive Clinical Research
    Berlin, New Jersey 08009, United States
  • Drug Trials America - New York
    Hartsdale, New York 10530, United States
  • New York Spine and Wellness Center
    North Syracuse, New York 13212, United States
  • Upstate Clinical Research Associates
    Williamsville, New York 14221, United States
  • Center for Clinical Research, LLC - Winston-Salem
    Winston-Salem, North Carolina 27103, United States
  • Columbus Clinical Research, Inc.
    Columbus, Ohio 43213, United States
  • Allegheny Pain Management, PC
    Altoona, Pennsylvania 16602, United States
  • FutureSearch Trials of Neurology
    Austin, Texas 78731, United States
  • KRK Medical Research
    Dallas, Texas 75230, United States
  • Benchmark Research - Fort Worth
    Fort Worth, Texas 76135, United States
  • Quality Research, Inc.
    San Antonio, Texas 78209, United States
  • Lifetree Clinical Research
    Salt Lake City, Utah 84106, United States
  • Hypothetest, LLC
    Roanoke, Virginia 24018, United States
09

References and documents

Publications

  • Gimbel JS, Rauck RL, Bass A, Wilson J, Pixton G, Malhotra B, Wilson G, Wolfram G. Effects of naltrexone exposure observed in two phase three studies with ALO-02, an extended-release oxycodone surrounding sequestered naltrexone. J Opioid Manag. 2019 Sep/Oct;15(5):417-427. doi: 10.5055/jom.2019.0530. PubMed 31849032 ↗
  • Wilson JG, Bass A, Pixton GC, Wolfram G, Rauck RL. Safety and tolerability of ALO-02 (oxycodone hydrochloride and sequestered naltrexone hydrochloride) extended-release capsules in older patients: a pooled analysis of two clinical trials. Curr Med Res Opin. 2020 Jan;36(1):91-99. doi: 10.1080/03007995.2019.1661679. Epub 2019 Sep 17. PubMed 31456431 ↗
  • Arora S, Setnik B, Michael D, Hudson JD, Clemmer R, Meisner P, Pixton GC, Goli V, Sommerville KW. A multicenter, 12-month, open-label, single-arm safety study of oxycodone-hydrochloride/naltrexone-hydrochloride extended-release capsules (ALO-02) in patients with moderate-to-severe chronic noncancer pain. J Opioid Manag. 2014 Nov-Dec;10(6):423-36. doi: 10.5055/jom.2014.0239. PubMed 25531960 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2010, a primary completion of May 2012 and a completion of May 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2016, 4 years 6 months after primary completion. A results delay was requested in Jul 2013.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 2, 2011
First posted
Sep 5, 2011
Start
Dec 2010
Primary completionActual
May 2012
CompletionActual
May 2012
Results delay requested
Jul 8, 2013
Results first posted
Nov 21, 2016
Last update
Nov 21, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 21, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01428583
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Sep 5, 2011
Start date
Dec 2010
Primary completion
May 2012
Completion
May 2012
Results posted
Nov 21, 2016
Last update
Nov 21, 2016

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Oxycodone · Naltrexone

Start the discussion